| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7438 R21944 |
Bérard, 2017 | Genital organs malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.50 [0.07;3.35] | -/191 -/14,847 | - | 191 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5882 R14692 |
Ban (Controls unexposed, disease free), 2014 | Genital system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) |
0.38 [0.16;0.93] excluded (control group) |
-/3,189 1,292/325,294 | - | 3,189 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5883 R14713 |
Ban (Controls unexposed, sick), 2014 | Genital system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.31 [0.12;0.76] | -/3,189 67/13,432 | - | 3,189 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10218 R37435 |
De Jonge, 2013 | Genital malformations | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 0.71 [0.04;11.50] C | 0/65 314/29,472 | 314 | 65 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6016 R15534 |
Jimenez-Solem (Controls unexposed, NOS), 2012 | Congenital malformations of the external genital organs | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) |
1.09 [0.35;3.38] excluded (control group) |
3/928 2,504/843,797 | 2,507 | 928 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6021 R15615 |
Jimenez-Solem (Controls unexposed, sick), 2012 | Congenital malformations of the external genital organs | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.30 [0.22;7.82] C | 3/928 2/806 | 5 | 928 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 0.45 [0.21;0.92] | 319 | 4,373 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 6016, 5882